WO2007095318A3 - Influenza antigens, vaccine compositions, and related methods - Google Patents
Influenza antigens, vaccine compositions, and related methods Download PDFInfo
- Publication number
- WO2007095318A3 WO2007095318A3 PCT/US2007/003969 US2007003969W WO2007095318A3 WO 2007095318 A3 WO2007095318 A3 WO 2007095318A3 US 2007003969 W US2007003969 W US 2007003969W WO 2007095318 A3 WO2007095318 A3 WO 2007095318A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine compositions
- related methods
- antigens
- influenza antigens
- compositions
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2448—Licheninase (3.2.1.73)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01073—Licheninase (3.2.1.73)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/517—Plant cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007215080A AU2007215080A1 (en) | 2006-02-13 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
EP07750784A EP1984405A4 (en) | 2006-02-13 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
JP2008554442A JP2009526526A (en) | 2006-02-13 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
BRPI0707733A BRPI0707733B1 (en) | 2006-02-13 | 2007-02-13 | isolated antigen, vaccine composition, use of said composition and method for producing an antigen protein |
CN2007800080983A CN101454347B (en) | 2006-02-13 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
CA2642054A CA2642054C (en) | 2006-02-13 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
IL193391A IL193391A0 (en) | 2002-06-15 | 2008-08-12 | Influenza antigens, vaccine compositions, and related methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77337806P | 2006-02-13 | 2006-02-13 | |
US60/773,378 | 2006-02-13 | ||
US81395506P | 2006-06-15 | 2006-06-15 | |
US60/813,955 | 2006-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007095318A2 WO2007095318A2 (en) | 2007-08-23 |
WO2007095318A3 true WO2007095318A3 (en) | 2007-10-25 |
Family
ID=38372128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/003969 WO2007095318A2 (en) | 2002-06-15 | 2007-02-13 | Influenza antigens, vaccine compositions, and related methods |
Country Status (9)
Country | Link |
---|---|
US (1) | US8124103B2 (en) |
EP (1) | EP1984405A4 (en) |
JP (1) | JP2009526526A (en) |
KR (1) | KR20080106433A (en) |
CN (1) | CN101454347B (en) |
AU (1) | AU2007215080A1 (en) |
BR (1) | BRPI0707733B1 (en) |
CA (1) | CA2642054C (en) |
WO (1) | WO2007095318A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8945580B2 (en) | 2007-07-11 | 2015-02-03 | Ibio Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
US8962278B2 (en) | 2005-08-03 | 2015-02-24 | Ibio Inc. | Compositions and methods for production of immunoglobulins |
US9012199B2 (en) | 2003-05-22 | 2015-04-21 | Ibio, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
US9115201B2 (en) | 2008-09-28 | 2015-08-25 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
WO2007095320A2 (en) * | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Hpv antigens, vaccine compositions, and related methods |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
EP2223934B1 (en) * | 2007-11-14 | 2012-10-03 | Institute Of Microbiology, Chinese Academy Of Sciences | Polypeptides for inhibiting influenza virus infection |
JP2011509661A (en) | 2007-11-27 | 2011-03-31 | メディカゴ インコーポレイテッド | Recombinant influenza virus-like particles (VLP) produced in transgenic plants expressing hemagglutinin |
WO2009152518A1 (en) * | 2008-06-13 | 2009-12-17 | Wisconsin Alumni Research Foundation | Novel peptide adjuvant for influenza vaccination |
CA2727898A1 (en) | 2008-06-13 | 2009-12-17 | Wisconsin Alumni Research Foundation | Novel antiviral peptides against influenza virus |
ES2545607T3 (en) | 2008-07-08 | 2015-09-14 | Medicago Inc. | Soluble Recombinant Flu Antigens |
WO2010006452A1 (en) | 2008-07-18 | 2010-01-21 | Medicago Inc. | New influenza virus immunizing epitope |
US20120034253A1 (en) * | 2008-09-25 | 2012-02-09 | Fraunhofer Usa, Inc. | Influenza Vaccines, Antigens, Compositions, and Methods |
KR101046004B1 (en) * | 2008-11-12 | 2011-07-01 | 서울대학교산학협력단 | How to diagnose swine influenza serum |
US20140205619A1 (en) * | 2008-11-28 | 2014-07-24 | Biolex Therapeutics, Inc. | Recombinant avian influenza vaccine and uses thereof |
WO2010088393A2 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-kay hybrid peptides that modulate the immune response to influenza |
WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
MX349924B (en) | 2009-06-24 | 2017-08-21 | Medicago Inc * | Chimeric influenza virus-like particles comprising hemagglutinin. |
IL300625A (en) | 2009-08-28 | 2023-04-01 | Icahn School Med Mount Sinai | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
AU2010300033B2 (en) | 2009-09-22 | 2015-01-22 | Medicago Inc. | Method of preparing plant-derived VLPS |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
MX2012011300A (en) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Influenza virus vaccines and uses thereof. |
EP2558120A4 (en) | 2010-04-15 | 2013-08-28 | Shin Nippon Biomedical Lab Ltd | Methods and compositions for intranasal delivery |
WO2011138032A2 (en) * | 2010-05-05 | 2011-11-10 | Artemev, Timur | Universal influenza vaccines and methods for their generation |
TWI620816B (en) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | Method of recovering plant-derived proteins |
EP4241785A3 (en) | 2011-09-20 | 2023-09-27 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
EP4154907A1 (en) | 2012-12-18 | 2023-03-29 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
ES2864081T3 (en) | 2014-01-10 | 2021-10-13 | Medicago Inc | CPMV enhancers |
CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
BR112018075032A2 (en) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | influenza virus hemagglutinin proteins and their use |
CA3058652A1 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
KR20200060969A (en) * | 2018-11-23 | 2020-06-02 | (주)셀트리온 | Dosage Regimen For Treating Influenza Virus-Related Disease |
MX2019014943A (en) * | 2018-12-12 | 2020-08-06 | Cambridge Tech Llc | Universal influenza vaccine. |
KR102444024B1 (en) * | 2019-06-17 | 2022-09-20 | 주식회사 바이오앱 | Recombinant vectors for the preparation of antigens for diagnosis of African swine fever and uses thereof |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
JPS61176721A (en) | 1985-01-31 | 1986-08-08 | Mochizuki Motor Kk | Opening and closing transporting device for manhole lid |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5316931A (en) | 1988-02-26 | 1994-05-31 | Biosource Genetics Corp. | Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
FR2638359A1 (en) | 1988-11-03 | 1990-05-04 | Tino Dalto | SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
HU219537B (en) | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (en) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | INJECTION NEEDLE ARRANGEMENT |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
ZA931148B (en) | 1992-02-19 | 1993-08-18 | Schering Corp | Cloning and expression of humanized monoclonal antibodies against human interfluekin-4. |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US6004554A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
NZ502568A (en) | 1997-08-05 | 2003-01-31 | Stressgen Biotechnologies Corp | Compositions to enhance immune responses against HPV (human papilloma virus) protein antigens and against tumours exhibiting an HPV protein antigen |
US6037456A (en) | 1998-03-10 | 2000-03-14 | Biosource Technologies, Inc. | Process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
US6044555A (en) | 1998-05-04 | 2000-04-04 | Keystone Powered Metal Company | Method for producing fully dense powdered metal helical gear |
NZ510358A (en) | 1998-08-11 | 2002-09-27 | Large Scale Biology Corp | Method for recovering proteins from the interstitial fluid of plant tissues |
HUP0103616A3 (en) | 1998-10-07 | 2003-07-28 | Syngenta Participations Ag | Therapeutically active proteins in plants |
EP1077600A4 (en) | 1998-10-30 | 2003-04-09 | Univ Jefferson | Production of biomedical peptides and proteins in plants using plant virus vectors |
CA2360670A1 (en) | 1999-02-05 | 2000-08-10 | Hilary Koprowski | Production of biomedical peptides and proteins in plants using transcomplementation systems |
JP2003528068A (en) * | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | New amphiphilic aldehydes and their use as adjuvants and immune effectors |
JP5008244B2 (en) * | 2000-06-23 | 2012-08-22 | ワイス・ホールディングズ・コーポレイション | Assembly of wild-type and chimeric influenza virus-like particles (VLPs) |
DK1296711T3 (en) | 2000-06-26 | 2006-08-28 | Stressgen Biotechnologies Corp | HPV-E7 for the treatment of human papillomavirus |
UA80809C2 (en) | 2001-11-05 | 2007-11-12 | Process for preparation of protective antigen protein of anthracis with e.coli | |
US20040170606A1 (en) | 2002-06-07 | 2004-09-02 | Palmer Kenneth E. | Production of peptides in plants as viral coat protein fusions |
US7683238B2 (en) | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
US7491509B2 (en) | 2003-02-03 | 2009-02-17 | Fraunhofer Usa, Inc. | System for expression of genes in plants |
WO2004098530A2 (en) | 2003-05-05 | 2004-11-18 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
ATE473271T1 (en) * | 2003-05-05 | 2010-07-15 | Thompson Boyce Plant Res | VECTORS AND CELLS FOR PRODUCING IMMUNOPROTECTIVE COMPOSITIONS OBTAINED FROM TRANSGENIC PLANTS |
ES2427641T3 (en) * | 2003-05-22 | 2013-10-31 | Ibio, Inc. | Recombinant vehicle molecule for expression, delivery and purification of target polypeptides |
EP2581093B1 (en) * | 2003-06-16 | 2015-03-18 | MedImmune, LLC | Influenza hemagglutinin and neuraminidase variants |
US7888135B2 (en) | 2004-04-23 | 2011-02-15 | University Of Georgia Research Foundation, Inc. | Diagnostic assay for Trypanosoma cruzi infection |
EP1771552B1 (en) * | 2004-05-25 | 2012-08-01 | MedImmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
WO2007095320A2 (en) | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Hpv antigens, vaccine compositions, and related methods |
WO2008033105A1 (en) | 2006-09-13 | 2008-03-20 | Dso National Laboratories | Hemagglutinin antibody and uses thereof |
AU2007295073A1 (en) | 2006-09-15 | 2008-03-20 | Fraunhofer Usa, Inc. | Influenza antibodies, compositions, and related methods |
US8778348B2 (en) | 2007-04-28 | 2014-07-15 | Ibio Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
US8404252B2 (en) | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
US20110059130A1 (en) | 2007-08-20 | 2011-03-10 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods |
US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
-
2007
- 2007-02-13 EP EP07750784A patent/EP1984405A4/en not_active Withdrawn
- 2007-02-13 JP JP2008554442A patent/JP2009526526A/en not_active Withdrawn
- 2007-02-13 KR KR1020087022551A patent/KR20080106433A/en not_active Application Discontinuation
- 2007-02-13 CN CN2007800080983A patent/CN101454347B/en active Active
- 2007-02-13 AU AU2007215080A patent/AU2007215080A1/en not_active Abandoned
- 2007-02-13 US US11/706,573 patent/US8124103B2/en active Active
- 2007-02-13 WO PCT/US2007/003969 patent/WO2007095318A2/en active Application Filing
- 2007-02-13 BR BRPI0707733A patent/BRPI0707733B1/en not_active IP Right Cessation
- 2007-02-13 CA CA2642054A patent/CA2642054C/en active Active
Non-Patent Citations (5)
Title |
---|
BRETT I.C. ET AL.: "Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system", VIROLOGY, vol. 339, no. 2, 1 September 2005 (2005-09-01), pages 273 - 280, XP005030984 * |
BUSCAGLIA C.A. ET AL.: "Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood", BLOOD, vol. 93, no. 6, 15 March 1999 (1999-03-15), pages 2025 - 2032, XP003022250 * |
CORBEL M.J.: "Reasons for instability of bacterial vaccines", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, vol. 87, 1996, pages 113 - 124, XP008012002 * |
COSTA M.H. ET AL.: "Conformational stability and antibody response to the 18kDa heat-shock protein formulated into different vehicles", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 73, no. 1, April 1998 (1998-04-01), pages 19 - 28, XP003022251 * |
MUSIYCHUK K. ET AL.: "Preparation and properties of Clostridium thermocellum lichenase deletion variants and their use for construction of bifunctional hybrid proteins", BIOCHEMISTRY (MOSC), vol. 65, no. 12, December 2000 (2000-12-01), pages 1397 - 1402, XP008059495 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012199B2 (en) | 2003-05-22 | 2015-04-21 | Ibio, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
US8962278B2 (en) | 2005-08-03 | 2015-02-24 | Ibio Inc. | Compositions and methods for production of immunoglobulins |
US8945580B2 (en) | 2007-07-11 | 2015-02-03 | Ibio Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
US9115201B2 (en) | 2008-09-28 | 2015-08-25 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007095318A2 (en) | 2007-08-23 |
KR20080106433A (en) | 2008-12-05 |
BRPI0707733A2 (en) | 2011-05-10 |
CN101454347B (en) | 2013-07-24 |
BRPI0707733B1 (en) | 2019-12-31 |
EP1984405A2 (en) | 2008-10-29 |
CA2642054A1 (en) | 2007-08-23 |
CA2642054C (en) | 2017-11-21 |
CN101454347A (en) | 2009-06-10 |
EP1984405A4 (en) | 2010-06-30 |
US8124103B2 (en) | 2012-02-28 |
US20070275014A1 (en) | 2007-11-29 |
AU2007215080A1 (en) | 2007-08-23 |
JP2009526526A (en) | 2009-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
WO2009026397A3 (en) | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods | |
WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
WO2008048344A3 (en) | Bacillus anthracis antigens, vaccine compositions, and related methods | |
WO2007024941A3 (en) | Polyvalent vaccine | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
WO2010036970A3 (en) | Influenza vaccines, antigens, compositions, and methods | |
WO2010019262A3 (en) | Polyvalent vaccine | |
HK1207828A1 (en) | Cell-derived viral vaccines with low levels of residual cell dna dna | |
WO2009026465A3 (en) | Composition and methods of making and using influenza proteins | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
IL203869A (en) | Method for the manufcture of a preparation comprising virus or viral antigens and various aspects related thereto, uses thereof and a split virus vaccine preparation obtained by the method | |
CA2817005A1 (en) | Rabies glycoprotein virus-like particles (vlps) | |
DK2707393T3 (en) | FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A | |
WO2008054481A3 (en) | Improved inactivated influenza virus compositions | |
EP1934335A4 (en) | Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications | |
EA201001045A1 (en) | MODIFIED FLU VIRUS | |
EP1989316A4 (en) | Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions | |
WO2008115314A3 (en) | Flavivirus vaccine vector against influenza virus | |
WO2009080715A3 (en) | Vaccines for malaria | |
WO2006024240A3 (en) | Vaccine composition against hepatitis c virus | |
WO2012058493A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
DE60325838D1 (en) | IMIDAZOQUINOLINAMINE AS ADJUVANTIES FOR HIV DNA VACCINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780008098.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007215080 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642054 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 193391 Country of ref document: IL Ref document number: 2008554442 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007750784 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3538/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087022551 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07750784 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0707733 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080812 |